化合物Belizatinib T4257

Product Introduction
Bioactivity


英文名: Belizatinib

描述: Belizatinib (TSR-011) 是可口服的ALK 和 TRKA、TRKB、TRKC 双重抑制剂，对野生型重组 ALK 的IC50值为0.7 nM。

体外活性: 在临床试验中，Belizatinib具有抗肿瘤活性。

体内活性: In mouse models, Belizatinib can continuously and effectively inhibit ALK-dependent tumor growth.

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 60 mg/mL (103.85 mM)


关键字: Trk Receptor | CD246 | ALK tyrosine kinase receptor | TSR011 | Tropomyosin related kinase receptor | Belizatinib | TSR 011 | inhibit | Cluster of differentiation 246 | Inhibitor | Anaplastic lymphoma kinase | Anaplastic lymphoma kinase (ALK)

相关产品: Amitriptyline hydrochloride | PF-06733804 | AZ-23 | Cyclotraxin B acetate(1203586-72-4 free base) | Tepotinib | Trk-IN-4 | Sitravatinib | Larotrectinib sulfate | Taletrectinib | TrkB-IN-1

相关库: Drug Repurposing Compound Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Kinase Inhibitor Library | Anti-Cancer Active Compound Library | Tyrosine Kinase Inhibitor Library

化合物Belizatinib T4257信息由TargetMol中国为您提供，如您想了解更多关于化合物Belizatinib T4257报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途